Full-Time
Develops therapeutics targeting aging mechanisms
$130k - $160k/yr
Mid
San Carlos, CA, USA
This is an onsite position.
Retro Biosciences focuses on extending healthy human lifespan by ten years through the development of therapeutics that target the cellular mechanisms of aging. The company addresses the root causes of age-related diseases, which are responsible for a significant portion of healthcare costs. Its product development is organized into three main programs: cellular reprogramming, plasma-inspired therapeutics, and autophagy, each at different stages of progress. Retro Biosciences utilizes advanced technologies like single-cell multi-omics and computational biology to enhance its research and development efforts. Unlike many competitors, Retro Biosciences aims to prevent multiple diseases rather than just treating them, positioning itself uniquely in the biotech industry. The company's goal is to reduce healthcare expenses related to aging and improve the quality of life for individuals as they age.
Company Size
51-200
Company Stage
Early VC
Total Funding
$180M
Headquarters
Redwood City, California
Founded
2021
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Unlimited Paid Time Off
Paid Holidays
Parental Leave
Professional Development Budget
Sam Altman is backing Retro Biosciences with a new funding round of $1 billion to extend human lifespan.
Retro Biosciences, a biotech company backed by OpenAI CEO Sam Altman, plans to raise $1 billion to fund its project aimed at extending human lifespan by 10 years. Altman initially provided $180 million in seed funding and will contribute more in the Series A round.
OpenAI has developed a specialized AI model, GPT-4b Micro, in collaboration with Retro Biosciences, a startup focused on extending human lifespan by ten years.
OpenAI, in partnership with longevity startup Retro Biosciences, has reportedly developed an artificial intelligence model aimed at enhancing the efficiency of stem cell production.
Longevity biotech Retro Biosciences has entered into an $85 million agreement with Multiply Labs to enhance the production of its cell therapies aimed at age-related diseases.